Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance.
Atovaquone is a hydroxy-naphthoquinone that is used to treat parasitic and fungal infections including Plasmodium falciparum (malaria), Pneumocystis jivorecii (pneumonia) and Toxoplasma gondii (toxoplasmosis). It blocks mitochondrial oxidation of ubiquinol in these organisms by binding to the ubiquinol oxidation site of the cytochrome bc(1) complex. Failure of atovaquone treatment has been linked to the appearance of mutations in the mitochondrially encoded gene for cytochrome b. In order to determine the optimal parameters required for inhibition of respiration in parasites and pathogenic fungi and overcome drug resistance, we have synthesized and tested the inhibitory activity of novel hydroxy-naphthoquinones against blood stage P. falciparum and liver stage P. berghei and against cytochrome bc(1) complexes isolated from yeast strains bearing mutations in cytochrome b associated with resistance in Plasmodium, Pneumocystis, and Toxoplasma. One of the new inhibitors is highly effective against an atovaquone resistant Plasmodium and illustrates the type of modification to the hydroxy-naphthoquinone ring of atovaquone that might mitigate drug resistance.
Department of Biochemistry, Dartmouth Medical School, 7200 Vail, Hanover, NH 03755, USA.
Louise M
LM
Hughes
Charlotte A
CA
Lanteri
Michael T
MT
O'Neil
Jacob D
JD
Johnson
Gordon W
GW
Gribble
Bernard L
BL
Trumpower
D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology*; D000981:Antiprotozoal Agents / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D015195:Drug Design; D004351:Drug Resistance; D006801:Humans; D008288:Malaria / Q000469:parasitology; D015394:Molecular Structure; D009285:Naphthoquinones / Q000737:chemistry / Q000494:pharmacology*; D010961:Plasmodium / Q000187:drug effects / Q000235:genetics / Q000254:growth & development / Q000378:metabolism; D013329:Structure-Activity Relationship; D015003:Yeasts / Q000187:drug effects / Q000235:genetics / Q000378:metabolism
D000935:Antifungal Agents; D000981:Antiprotozoal Agents; D009285:Naphthoquinones
Antimicrob Agents Chemother. 1979 Dec;16(6):710-8
394674
J Biol Chem. 1972 Feb 25;247(4):1012-9
5010060
Biochim Biophys Acta. 2008 Sep;1777(9):1147-56
18498758
J Biol Chem. 2003 Aug 15;278(33):31303-11
12782631
Biochemistry. 2003 Nov 25;42(46):13637-45
14622010
Mol Pharmacol. 2008 May;73(5):1347-55
18319379
Methods Mol Med. 2002;72:517-20
12125149
Trends Parasitol. 2007 Oct;23(10):494-501
17826334
J Biol Chem. 2008 Jun 20;283(25):17542-9
18390544
J Am Chem Soc. 1948 Oct;70(10):3151-5
18891812
Mol Biochem Parasitol. 2006 Jan;145(1):60-70
16242190
J Biol Chem. 1982 Jul 25;257(14):8321-30
6282879
Biochim Biophys Acta. 1998 Jun 10;1365(1-2):125-34
9693731
J Parasitol. 1984 Oct;70(5):831-3
6150971
Antimicrob Agents Chemother. 2003 Sep;47(9):2725-31
12936966
Biochim Biophys Acta. 2007 Apr;1767(4):319-26
17383607
Biochim Biophys Acta. 2010 Jan;1797(1):38-43
19660431
J Biol Chem. 2005 Apr 29;280(17):17142-8
15718226
J Med Chem. 2010 Feb 11;53(3):1211-21
20067272
Biochim Biophys Acta. 1970 Sep 1;216(2):237-49
5504626
J Biol Chem. 1991 Aug 15;266(23):14958-63
1651316
Mol Microbiol. 1999 Aug;33(4):704-11
10447880
J Pharmacol Exp Ther. 1948 Oct;94(2):85-96
18889403
J Biol Chem. 2007 Aug 3;282(31):22289-97
17561507
Malar J. 2008 Nov 20;7:240
19021900
J Biol Chem. 2004 Jan 23;279(4):2817-24
14576156
Antimicrob Agents Chemother. 2008 Feb;52(2):684-93
17999964
Nature. 2007 Mar 1;446(7131):88-91
17330044
Antimicrob Agents Chemother. 1985 Apr;27(4):525-30
3890727
Mol Biochem Parasitol. 2000 Apr 30;108(1):1-12
10802314
J Med Chem. 2008 May 8;51(9):2845-52
18396855
J Antimicrob Chemother. 2007 Nov;60(5):929-36
17848375
J Pharm Sci. 2006 Dec;95(12):2657-72
16892205
Mol Biochem Parasitol. 2006 Apr;146(2):255-8
16412524
Mol Biochem Parasitol. 2008 May;159(1):64-8
18308406